arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vir Biotechnology, Inc.

VIR
$11.00 ▼ -0.77 (-6.54%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
36 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Vir Biotechnology, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.8B
Dividend Yield —
Revenue Growth 19582.5%
Op. Margin 30.7%
ROIC 7.5% ↗
FCF / Share $0.74 ↗
Trailing P/E 22.9x
Price / Book 1.9x
FCF Yield 6.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$238.95M
↑ +19582.5% —
Net Income Profit after all expenses
$80.08M
↑ +163.7% —
Operating Margin Operating profit as % of sales
30.7%
↑ +141.1% —
FCF / Share Free cash flow per share
$0.74
↑ +181.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 36 quarters